{"id":23366,"date":"2020-09-09T00:00:00","date_gmt":"2020-09-09T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/"},"modified":"2020-09-09T00:00:00","modified_gmt":"2020-09-09T05:00:00","slug":"loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/","title":{"rendered":"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes"},"content":{"rendered":"<p>Nous recommandons l&rsquo;utilisation de corticost&eacute;ro&iuml;des syst&eacute;miques pour le traitement des patients atteints d&rsquo;une forme grave ou critique de COVID-19. Nous sugg&eacute;rons de ne pas utiliser de corticost&eacute;ro&iuml;des pour traiter les patients atteints d&rsquo;une forme b&eacute;nigne de la maladie car, dans cette situation, le traitement ne pr&eacute;sente &nbsp;aucun avantage et pourrait m&ecirc;me s&rsquo;av&eacute;rer nocif. Le traitement doit &ecirc;tre pris sous surveillance m&eacute;dicale. Cliquez <strong><a href=\"https:\/\/www.who.int\/fr\/news-room\/feature-stories\/detail\/who-updates-clinical-care-guidance-with-corticosteroid-recommendations\" target=\"_blank\" rel=\"noopener\">ici<\/a>&nbsp;<\/strong>pour lire la suite.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nous recommandons l&rsquo;utilisation de corticost&eacute;ro&iuml;des syst&eacute;miques pour le traitement des patients atteints d&rsquo;une forme grave ou critique de COVID-19. Nous sugg&eacute;rons de ne pas utiliser de corticost&eacute;ro&iuml;des pour traiter les patients atteints d&rsquo;une forme b&eacute;nigne de la maladie car, dans cette situation, le traitement ne pr&eacute;sente &nbsp;aucun avantage et pourrait m&ecirc;me s&rsquo;av&eacute;rer nocif. Le traitement [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[72],"tags":[],"class_list":["post-23366","post","type-post","status-publish","format-standard","hentry","category-actualites-et-nouvelles-au-sujet-de-la-covid-19"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Nous recommandons l\u2019utilisation de corticost\u00e9ro\u00efdes syst\u00e9miques pour le traitement des patients atteints d\u2019une forme grave ou critique de COVID-19. Nous sugg\u00e9rons de ne pas utiliser de corticost\u00e9ro\u00efdes pour traiter les patients atteints d\u2019une forme b\u00e9nigne de la maladie car, dans cette situation, le traitement ne pr\u00e9sente aucun avantage et pourrait m\u00eame s\u2019av\u00e9rer nocif. Le traitement\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Nous recommandons l\u2019utilisation de corticost\u00e9ro\u00efdes syst\u00e9miques pour le traitement des patients atteints d\u2019une forme grave ou critique de COVID-19. Nous sugg\u00e9rons de ne pas utiliser de corticost\u00e9ro\u00efdes pour traiter les patients atteints d\u2019une forme b\u00e9nigne de la maladie car, dans cette situation, le traitement ne pr\u00e9sente aucun avantage et pourrait m\u00eame s\u2019av\u00e9rer nocif. Le traitement\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2020-09-09T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2020-09-09T05:00:00+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Nous recommandons l\u2019utilisation de corticost\u00e9ro\u00efdes syst\u00e9miques pour le traitement des patients atteints d\u2019une forme grave ou critique de COVID-19. Nous sugg\u00e9rons de ne pas utiliser de corticost\u00e9ro\u00efdes pour traiter les patients atteints d\u2019une forme b\u00e9nigne de la maladie car, dans cette situation, le traitement ne pr\u00e9sente aucun avantage et pourrait m\u00eame s\u2019av\u00e9rer nocif. Le traitement\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#blogposting\",\"name\":\"L\\u2019OMS ajoute \\u00e0 ses orientations cliniques des recommandations sur l\\u2019utilisation des corticost\\u00e9ro\\u00efdes | My\\u00e9lome Canada\",\"headline\":\"L\\u2019OMS ajoute \\u00e0 ses orientations cliniques des recommandations sur l\\u2019utilisation des corticost\\u00e9ro\\u00efdes\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2020-09-09T00:00:00-05:00\",\"dateModified\":\"2020-09-09T00:00:00-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et nouvelles au sujet de la COVID-19, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"position\":2,\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites-et-nouvelles-au-sujet-de-la-covid-19\\\/#listItem\",\"name\":\"Actualit\\u00e9s et nouvelles au sujet de la COVID-19\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites-et-nouvelles-au-sujet-de-la-covid-19\\\/#listItem\",\"position\":3,\"name\":\"Actualit\\u00e9s et nouvelles au sujet de la COVID-19\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites-et-nouvelles-au-sujet-de-la-covid-19\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#listItem\",\"name\":\"L\\u2019OMS ajoute \\u00e0 ses orientations cliniques des recommandations sur l\\u2019utilisation des corticost\\u00e9ro\\u00efdes\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#listItem\",\"position\":4,\"name\":\"L\\u2019OMS ajoute \\u00e0 ses orientations cliniques des recommandations sur l\\u2019utilisation des corticost\\u00e9ro\\u00efdes\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites-et-nouvelles-au-sujet-de-la-covid-19\\\/#listItem\",\"name\":\"Actualit\\u00e9s et nouvelles au sujet de la COVID-19\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/\",\"name\":\"L\\u2019OMS ajoute \\u00e0 ses orientations cliniques des recommandations sur l\\u2019utilisation des corticost\\u00e9ro\\u00efdes | My\\u00e9lome Canada\",\"description\":\"Nous recommandons l\\u2019utilisation de corticost\\u00e9ro\\u00efdes syst\\u00e9miques pour le traitement des patients atteints d\\u2019une forme grave ou critique de COVID-19. Nous sugg\\u00e9rons de ne pas utiliser de corticost\\u00e9ro\\u00efdes pour traiter les patients atteints d\\u2019une forme b\\u00e9nigne de la maladie car, dans cette situation, le traitement ne pr\\u00e9sente aucun avantage et pourrait m\\u00eame s\\u2019av\\u00e9rer nocif. Le traitement\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/09\\\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2020-09-09T00:00:00-05:00\",\"dateModified\":\"2020-09-09T00:00:00-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes | My\u00e9lome Canada","description":"Nous recommandons l\u2019utilisation de corticost\u00e9ro\u00efdes syst\u00e9miques pour le traitement des patients atteints d\u2019une forme grave ou critique de COVID-19. Nous sugg\u00e9rons de ne pas utiliser de corticost\u00e9ro\u00efdes pour traiter les patients atteints d\u2019une forme b\u00e9nigne de la maladie car, dans cette situation, le traitement ne pr\u00e9sente aucun avantage et pourrait m\u00eame s\u2019av\u00e9rer nocif. Le traitement","canonical_url":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#blogposting","name":"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes | My\u00e9lome Canada","headline":"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2020-09-09T00:00:00-05:00","dateModified":"2020-09-09T00:00:00-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#webpage"},"articleSection":"Actualit\u00e9s et nouvelles au sujet de la COVID-19, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","position":2,"name":"Actualit\u00e9s et \u00e9v\u00e9nement","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites-et-nouvelles-au-sujet-de-la-covid-19\/#listItem","name":"Actualit\u00e9s et nouvelles au sujet de la COVID-19"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites-et-nouvelles-au-sujet-de-la-covid-19\/#listItem","position":3,"name":"Actualit\u00e9s et nouvelles au sujet de la COVID-19","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites-et-nouvelles-au-sujet-de-la-covid-19\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#listItem","name":"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#listItem","position":4,"name":"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites-et-nouvelles-au-sujet-de-la-covid-19\/#listItem","name":"Actualit\u00e9s et nouvelles au sujet de la COVID-19"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/","name":"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes | My\u00e9lome Canada","description":"Nous recommandons l\u2019utilisation de corticost\u00e9ro\u00efdes syst\u00e9miques pour le traitement des patients atteints d\u2019une forme grave ou critique de COVID-19. Nous sugg\u00e9rons de ne pas utiliser de corticost\u00e9ro\u00efdes pour traiter les patients atteints d\u2019une forme b\u00e9nigne de la maladie car, dans cette situation, le traitement ne pr\u00e9sente aucun avantage et pourrait m\u00eame s\u2019av\u00e9rer nocif. Le traitement","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2020-09-09T00:00:00-05:00","dateModified":"2020-09-09T00:00:00-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes | My\u00e9lome Canada","og:description":"Nous recommandons l\u2019utilisation de corticost\u00e9ro\u00efdes syst\u00e9miques pour le traitement des patients atteints d\u2019une forme grave ou critique de COVID-19. Nous sugg\u00e9rons de ne pas utiliser de corticost\u00e9ro\u00efdes pour traiter les patients atteints d\u2019une forme b\u00e9nigne de la maladie car, dans cette situation, le traitement ne pr\u00e9sente aucun avantage et pourrait m\u00eame s\u2019av\u00e9rer nocif. Le traitement","og:url":"https:\/\/myeloma.ca\/fr\/2020\/09\/09\/loms-ajoute-a-ses-orientations-cliniques-des-recommandations-sur-lutilisation-des-corticosteroides\/","article:published_time":"2020-09-09T05:00:00+00:00","article:modified_time":"2020-09-09T05:00:00+00:00","twitter:card":"summary_large_image","twitter:title":"L\u2019OMS ajoute \u00e0 ses orientations cliniques des recommandations sur l\u2019utilisation des corticost\u00e9ro\u00efdes | My\u00e9lome Canada","twitter:description":"Nous recommandons l\u2019utilisation de corticost\u00e9ro\u00efdes syst\u00e9miques pour le traitement des patients atteints d\u2019une forme grave ou critique de COVID-19. Nous sugg\u00e9rons de ne pas utiliser de corticost\u00e9ro\u00efdes pour traiter les patients atteints d\u2019une forme b\u00e9nigne de la maladie car, dans cette situation, le traitement ne pr\u00e9sente aucun avantage et pourrait m\u00eame s\u2019av\u00e9rer nocif. Le traitement"},"aioseo_meta_data":{"post_id":"23366","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-10-26 14:23:25","updated":"2026-04-30 08:06:57","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/23366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=23366"}],"version-history":[{"count":0,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/23366\/revisions"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=23366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=23366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=23366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}